Takeda Pharmaceuticals U.S.A. Inc. and Cognition Kit Limited are partnering to pilot an app for the Apple Watch to monitor and assess cognitive function in patients with major depressive disorder (MDD).
The Cognition Kit app helps test cognitive function, which may be underrecognized by patients and doctors, and provides monitoring in everyday life to engage patients in their treatment.
Thirty people age 18-65 who have been diagnosed with mild to moderate depression and prescribed an antidepressant for MDD will participate in the study.
The study will evaluate how measurements of people's mood and cognition on their wearable devices compares to traditional testing and patient-reported assessments. Results from the study are expected later this year.
"This collaboration is part of our strategy to embrace new technology to better understand the patient experience and assist health care professionals in creating improved patient care pathways," Mowad-Nassar, vice president of external partnerships at Takeda Pharmaceuticals U.S.A., said in a company press release.
